Research
Awards Grant
A5361s: Pitavastatin to Reduce Physical Function Impairment and Frailty in HIV (PREPARE)
ACTG Protocol Funds
AIDS Clinical Trials Group (ACTG)
AIDS Clinical Trials Group Laboratory Center (ACTG)
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections [ACTG LOC: PF Chair A5332]
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections [ACTG LOC: PF Chair A5359]
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections [ACTG LOC: TSG-Sci Comm] Sub award# 1560 G YB529
Ancillary to ABC PICU to Study MOD in Critically Ill Children
Biological Vulnerability to Chlamydia Trachomatis in Adolescents and Young Women: The Complex Intersection of Cervicovaginal Microbiome, Cervical Maturation, and Mucosal Immunity
Clinical Study of STI Screening to Prevent Adverse Birth and Newborn Outcomes
Does Aggressive Treatment in Early RA Reduce Biomarkers of Cardiovascular Risk?
Genomic Classification of the Heart Transplant Endomyocardial Biopsy
Il-21 and Immune Mediated Viral Control, IMVC Pilot Project: "Mechanisms of IL-21 Mediated Immunity"
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group
International Maternal, Adolescent and Pediatric Therapeutics Clinical Trials Network (IMPAACT LC)
Leadership And Operations Center (LOC), AIDS Clinical Trial Group (ACTG) (UM1AI068636)
Leadership And Operations Center (LOC), AIDS Clinical Trials Group (ACT6) [UM1AI068636]-A5332 Committee Chair Support
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) (UM1A068636-13)
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/ [Specialty Lab Fixed Rate]
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/[PF Spec. Lab]
UAB 1356 - A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotropic Liver Transplant (OLT) Recipients with Hepatocellular Carcinoma (HCC)
UAB 1356: A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients with Hepatocellular Carcinoma (HCC)
